Clinical Trials Logo
  1. Home
  2. ANCA-associated Vasculitis
  3. NCT04923074

the Application of Diffusion Tensor Imaging in the Evaluation of Peripheral Neuropathy in ANCA Associated Vasculitis

ANCA Associated Vasculitis Clinical Trial

Official title:
the Application of Diffusion Tensor Imaging(DTI) in the Evaluation of Peripheral Neuropathy in Anti-neutrophil Cytoplasmic Antibodies Associated Vasculitis(AAV)

Clinical Trial Summary

1. Include qualified 50 ANCA-associated vasculitis(AAV) patients; and the first 27 patients will be divided into 3 groups with different diffused tension image (DTI) parameters and to choose the best strategy； 2. On baseline, 6 months after treatment and 24 months after treatment, the AAV patients will accomplish the Birming-ham vasculitis activity score(BVAS) besides DTI； 3. The new serum biomarkers of AAV associated peripheral neuropathy will be measured by ELISA； (4) Another cohort with 50 patients with AAV associated peripheral neuropathy who were evaluated by traditional methods (electromyogram) and compared to the patients cohort that evaluated using DTI by cost-benefit analysis

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04923074
Study type Observational
Source Second Affiliated Hospital, School of Medicine, Zhejiang University
Contact wenjia sun
Phone 86 15869029727
Email sunwinjoy@zju.edu.cn
Status Recruiting
Phase
Start date July 2021
Completion date July 2023
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT03942887 - Exploring Durable Remission With Rituximab in Antineutrophil Cytoplasmic Antibody(ANCA)-Associated Vasculitis Phase 3
Completed NCT04895878 - Patients With Co-occurrence of ANCA Vasculitis and Sjögren Syndrome
Completed NCT00293072 - Pilot Study of Rituximab Therapy for Systemic Lupus Erythematosus (SLE) and Vasculitis Phase 2
Recruiting NCT04664465 - PRediction Of DIverse Glucocorticoids toxIcity OUtcomeS
Recruiting NCT05315141 - Multicenter Cohort Study of AAV in Hunan of China
Recruiting NCT05376319 - PR3-AAV Resilient Remission or PRRR Phase 2
Recruiting NCT04737343 - Comparison of the Efficacy of Leflunomide and Azathioprine for the Maintenance Therapy of ANCA Associated Vasculitis N/A
Recruiting NCT05962840 - Efficacy and Safety for Rituximab Combined With Telitacicept in the Treatment of ANCA-associated Vasculitis (TTCAAVREM) Phase 4
Suspended NCT03906227 - Tailoring Maintenance Therapy to Cluster of Differentiation 5 Positive (CD5+) Regulatory B Cell Recovery in ANCA Vasculitis N/A
Not yet recruiting NCT06152172 - CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101 Phase 1
Not yet recruiting NCT05946564 - A Trial to Evaluate the Efficacy of Pioglitazone to Promote Renal Tolerance in ANCA-associated Vasculitis - RENATO Trial Phase 3
Active, not recruiting NCT01633476 - CMV Modulation of the Immune System in ANCA-associated Vasculitis Phase 2
Not yet recruiting NCT05416723 - Occupational and Environmental Origins of ANCA Vasculitis: Contribution of Data From the National Network for Vigilance and Prevention of Occupational Pathologies (RNV3P)
Recruiting NCT06277427 - Refractory ANCA Associated Vasculitis and Lupus Nephritis Treated With BCMA-targeting CAR-T Cells N/A
Active, not recruiting NCT03967925 - Rituximab and Belimumab Combination Therapy in PR3 Vasculitis Phase 2
Recruiting NCT05630612 - ETA and AT1 Antagonism in ANCA-vasculitis (SPARVASC) Phase 2
Recruiting NCT04316494 - Hydroxychloroquine in ANCA Vasculitis Evaluation Phase 4
Recruiting NCT03698071 - Soluble CD95 Ligand Role in the Pathophysiology of Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis N/A
Completed NCT04973033 - Effect of Tofacitinib in Treating ANCA-associated Vasculitis N/A
Recruiting NCT06373081 - Anti-CD19-CD3E-CAR-T Cells in Relapsed/Refractory Autoimmune Disease N/A